Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosures
3. The commonest cause of chronic inflammatory polyarthritis
4. History
5. Prevalence and outcome of rheumatoid arthritis
6. Prevalence of RA in world populations
7. Joint involvement in early RA
8. Tenderness of MTP joints in early disease
9. Rheumatoid hand deformities
10. Correlation between disability and inflammation in RA
11. Shortened life-span in severe RA
12. RA and increased mortality
13. RA and IHD
14. Long-term outcomes in RA
15. Extra-articular features in RA
16. The fate of RA
17. Long-term outcome
18. Why do patients with RA see a doctor?
19. Classification vs. diagnosis
20. 1987 ACR classification criteria for RA
21. 2010 ACR/EULAR classification criteria for RA
22. 2010 ACR/EULAR classification and “target” population
23. Useful classification tests
24. Rheumatoid factors in RA
25. Anti-citrullinated cyclic-peptide antibodies (ACPA)
26. Imaging -progression of damage
27. Erosions by radiography
28. Detection of erosions (1)
29. Detection of erosions (2)
30. Aetiology and pathophysiology
31. Aetiology: genetic component
32. Class II genes is associated with susceptibility to RA
33. Initiation of RA
34. Non-genetic factors
35. Evolution of RA (1)
36. Dissecting gene-gene environment interactions
37. Evolution of RA (2)
38. Immune and inflammatory responses stimulated the pathogenesis of RA
39. Cytokines drive the inflammatory response in RA
40. Cytokines work within a complex regulatory network
41. Cytokines systemic and local effects
42. Cytokines are implicated in each phase of RA pathogenesis
43. TNFa in RA synovium
44. Key actions of TNF in RA pathogenesis
45. TNF, IL-6 and IL-1 in RA
46. Cytokines and joint tissue destruction
47. Various cells and cytokines play key roles in RA
48. The role of IL-6 in RA
49. The role of cytokines in B cell proliferation and differentiation
50. The role of B cells in RA
51. The role of cytokines in T helper cell differentiation
52. The role of T cells in RA
53. Role of cytokines in the cycle of chronic inflammation
54. Extracellular and cell-associated therapeutic targets in RA
55. Approaches to targeted therapies

Topics Covered

• Prevalence, heterogeneous presentation, and disease course of rheumatoid arthritis
• Classification criteria and radiology
• Aetiology and pathophysiology
• The role of the immune system and inflammation in rheumatoid arthritis

Links

Categories:

• Clinical Medicine
• Diseases, Disorders & Treatments
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on May 31, 2020

Financial Disclosures

• Research grants from Celgene, Galapagos, Janssen, Lilly. Consultation fees from AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Lilly, Pfizer, Roche, Sanofi, Nordic Pharma, Fresenius and UCB.